Board of Directors

Mark Capone

Mark Capone has served as a member of our Board of Directors since July 2026 and is a seasoned healthcare executive with more than 40 years of leadership experience across the diagnostics and life sciences sectors. Previously, he served as Chief Executive Officer of Myriad Genetics, where he led the company’s transformation into a focused precision medicine organization, expanding its molecular diagnostics portfolio and strengthening its commercial execution. Prior to serving as CEO, he held several senior leadership roles at Myriad during his 17-year tenure, including President and Chief Operating Officer. Earlier in his career, Mr. Capone held leadership positions at Eli Lilly and other healthcare organizations, building deep expertise in pharmaceutical commercialization, strategic planning, and business development. He currently serves as a non-executive director at Mesa Laboratories, where he is Chair of the Compensation Committee, and at Owlstone Medical, where he serves on the Compensation Committee. Mr. Capone received a Master of Science in Chemical Engineering and a Master of Science in Management from the Massachusetts Institute of Technology, and a Bachelor of Science in Chemical Engineering from Pennsylvania State University. We believe that Mr. Capone’s qualifications to serve on our Board of Directors include his extensive experience commercializing complex diagnostic products, his deep understanding of reimbursement and payer environments, and his proven ability to scale innovative diagnostic platforms and build high-performing commercial organizations.

• 

  Member
  Compensation Committee